Homepage
About Us
Corporate Overview
Vision & Mission
Corporate Development Milestone
Leadership
Corporate Events
Products
Recombinant Human Collagen
Recombinant Type A Botulinum Toxin(In clinical trials)
Recombinant Human Growth Hormone(In clinical trials)
fadsfdsaf
fadsfdsaf
R&D
Recombinant Human Collagen
Recombinant Type A Botulinum Toxin
Recombinant Human Growth Hormone
Intellectual Property
Manufacturing
News
Join Us
Contact Us
中文
中文
Homepage
About Us
Corporate Overview
Vision & Mission
Corporate Development Milestone
Leadership
Corporate Events
Products
Recombinant Human Collagen
Recombinant Type A Botulinum Toxin(In clinical trials)
Recombinant Human Growth Hormone(In clinical trials)
fadsfdsaf
fadsfdsaf
R&D
Recombinant Human Collagen
Recombinant Type A Botulinum Toxin
Recombinant Human Growth Hormone
Intellectual Property
Manufacturing
News
Join Us
Contact Us
News
JHM Biopharmaceutical Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity
2024.09.14
JHM Biopharmaceutical Raises Nearly CN¥350 million in Series B and B+ Financing
2024.09.10
JHM Biopharmaceutical Receives Approval for Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke Spasticity
2024.08.21
JHM Biopharmaceutical Achieves Over 20-Ton Production Capacity for Recombinant Human Collagen
2024.06.27
News
JHM Biopharmaceutical Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity
2024.09.14
JHM Biopharmaceutical Raises Nearly CN¥350 million in Series B and B+ Financing
2024.09.10
JHM Biopharmaceutical Receives Approval for Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke Spasticity
2024.08.21
JHM Biopharmaceutical Achieves Over 20-Ton Production Capacity for Recombinant Human Collagen
2024.06.27